Novo Nordisk's Wegovy Oral Treatment Sales Surge in First Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy AMCR?
Source: CNBC
- Strong Oral Treatment Sales: Novo Nordisk's Wegovy oral weight loss treatment saw about 1.3% of prescriptions in its first week, leading to a stock price increase of over 4%, indicating strong market demand that could underpin future revenue growth.
- Disappointing Regional Bank Earnings: Regions Financial reported fourth-quarter earnings of 57 cents per share, falling short of the 61 cents forecasted by analysts, resulting in a nearly 3% drop in stock price, reflecting profitability pressures and diminished market confidence.
- Energy Stocks Rally: Energy stocks surged, with GE Vernova and Bloom Energy both gaining around 6% as the Trump administration encourages tech companies to fund power plants, signaling optimism in utility infrastructure investments that may drive long-term growth for these companies.
- Biotech Stock Surge: ImmunityBio's stock jumped 28%, adding to a 30% rally from the previous session, as the company anticipates a 700% increase in full-year revenue for its bladder cancer drug Anktiva, showcasing strong market potential and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMCR
Wall Street analysts forecast AMCR stock price to fall
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 49.740
Low
9.00
Averages
10.72
High
13.60
Current: 49.740
Low
9.00
Averages
10.72
High
13.60
About AMCR
Amcor plc is engaged in packaging solutions for consumer and healthcare products. The Company develops sustainable packaging in flexible and rigid formats across multiple materials. The Company operates through two segments: Flexibles and Rigid Packaging. The Flexibles segment consists of operations that manufacture flexible and film packaging in the food and beverage, medical and pharmaceutical, fresh produce, snack food, personal care, and other industries. The Rigid Packaging segment consists of operations that manufacture rigid containers for a broad range of predominantly beverage and food products, including carbonated soft drinks, water, juices, sports drinks, milk-based beverages, spirits and wine, sauces, dressings, spreads and personal care items, and plastic caps for a wide variety of applications. The Company's subsidiaries include Berry Global Group Inc., Amcor Flexibles North America, Inc., Amcor UK Finance plc, Amcor Finance (USA), Inc., and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SPYD ETF 52-Week Price Analysis
- Price Range Analysis: The SPYD ETF has a 52-week low of $37.92 and a high of $48.38, with the latest trade at $48.26, indicating stability near its high point, which aids investors in assessing market performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to identify market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, with investors buying and selling 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETFs.
See More
Biotech ETF Recommended, Amcor Reports Strong Earnings
- Biotech Investment Recommendation: Jason Snipe, founder of Odyssey Capital Advisors, recommended the iShares Biotechnology ETF (NYSE:IBB) on CNBC, emphasizing the potential for long-term investment in the biotech sector, reflecting confidence in future growth.
- Amcor's Strong Earnings: Amcor plc (NYSE:AMCR) reported second-quarter earnings of $0.86 per share on February 3, beating the analyst consensus of $0.85, although quarterly sales of $5.449 billion fell short of the $5.576 billion estimate, indicating strong profitability.
- Positive Stock Performance: Following the earnings report, Amcor's stock rose by 8.1% to close at $48.56, suggesting a favorable market reaction to its financial performance, which may attract more investor interest.
- Emerson Electric's Better-Than-Expected Results: Emerson Electric Co. (NYSE:EMR) reported first-quarter adjusted EPS of $1.46, exceeding the $1.41 consensus estimate, and raised its FY26 EPS guidance, showcasing ongoing growth potential in the industrial sector.
See More
NAN FUNG TRINITY Acquires New Stake in KT Corporation
- New Investment Position: On February 3, 2026, NAN FUNG TRINITY (HK) LTD disclosed a new position by acquiring 1,492,440 shares of KT Corporation for approximately $28.31 million, marking a strategic expansion in the telecommunications sector.
- Asset Allocation Enhancement: This acquisition positions KT to represent 2.24% of NAN FUNG TRINITY's reportable assets, becoming its 11th largest holding, indicating the firm's confidence in the telecom industry's growth potential.
- Strong Market Performance: As of February 3, 2026, KT shares were priced at $20.90, reflecting a 20.1% increase over the past year, outperforming the S&P 500 by 4.73 percentage points, showcasing market recognition of its business model and growth prospects.
- Valuation at a Discount: NAN FUNG TRINITY purchased KT at a P/E ratio of 15, with a forward P/E ratio of 6, suggesting the investment was made at a reasonable price, with potential for further share accumulation to strengthen its competitive position in the telecom market.
See More
Amcor plc Q2 2026 Earnings Call Highlights
- Stable Financial Performance: Amcor plc reported $5.4 billion in revenue for Q2 2026, with EBITDA at $826 million and adjusted EPS of $0.86, indicating robust financial performance in line with expectations despite weaker noncore business performance, showcasing the company's resilience post-Berry acquisition.
- Accelerated Synergy Realization: The company achieved $55 million in synergy benefits in Q2, a significant increase from $38 million in Q1, with total expected synergies for FY 2026 projected to exceed $260 million, enhancing profitability and laying a foundation for future growth.
- Free Cash Flow Guidance: Management reaffirmed free cash flow guidance for FY 2026 at $1.8 billion to $1.9 billion, reflecting ongoing efforts in cost control and operational efficiency aimed at achieving sustainable earnings growth amidst market challenges.
- Portfolio Optimization Progress: Amcor is evaluating alternatives for its $2.5 billion noncore businesses, including the North American beverage segment, emphasizing the importance of portfolio optimization to enhance overall business performance and maintain a competitive edge in a challenging market environment.
See More
Amcor (AMCR) Q2 2026 Earnings Call Transcript
See More
Amcor Q2 Earnings Beat Expectations with Strong Growth
- Earnings Beat Expectations: Amcor reported Q2 non-GAAP EPS of $0.86, exceeding estimates by $0.02, indicating ongoing improvement in profitability, although revenue of $5.44 billion, up 67.9% year-over-year, fell short of expectations by $70 million.
- Significant Acquisition Synergies: GAAP net income stood at $177 million, including acquisition-related costs, with GAAP diluted EPS at $0.38, while acquisition synergies reached $55 million, demonstrating the strategic success of the Berry acquisition.
- Adjusted EBITDA Growth: Adjusted EBITDA rose to $826 million, an 83% increase, with adjusted EBIT at $603 million, up 66%, reflecting significant improvements in cost control and operational efficiency, as adjusted EBITDA margin reached 15.2%, up from 14% last year.
- Optimistic Future Outlook: Amcor reaffirmed its fiscal 2026 guidance with adjusted EPS expected between $4.00 and $4.15, representing 12% to 17% constant currency growth, alongside projected free cash flow of $1.8 to $1.9 billion, highlighting strong cash generation capabilities.
See More
SPYD ETF 52-Week Price Analysis
- Price Range Analysis: The SPYD ETF has a 52-week low of $37.92 and a high of $48.38, with the latest trade at $48.26, indicating stability near its high point, which aids investors in assessing market performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to identify market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, with investors buying and selling 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETFs.
See More
Biotech ETF Recommended, Amcor Reports Strong Earnings
- Biotech Investment Recommendation: Jason Snipe, founder of Odyssey Capital Advisors, recommended the iShares Biotechnology ETF (NYSE:IBB) on CNBC, emphasizing the potential for long-term investment in the biotech sector, reflecting confidence in future growth.
- Amcor's Strong Earnings: Amcor plc (NYSE:AMCR) reported second-quarter earnings of $0.86 per share on February 3, beating the analyst consensus of $0.85, although quarterly sales of $5.449 billion fell short of the $5.576 billion estimate, indicating strong profitability.
- Positive Stock Performance: Following the earnings report, Amcor's stock rose by 8.1% to close at $48.56, suggesting a favorable market reaction to its financial performance, which may attract more investor interest.
- Emerson Electric's Better-Than-Expected Results: Emerson Electric Co. (NYSE:EMR) reported first-quarter adjusted EPS of $1.46, exceeding the $1.41 consensus estimate, and raised its FY26 EPS guidance, showcasing ongoing growth potential in the industrial sector.
See More
NAN FUNG TRINITY Acquires New Stake in KT Corporation
- New Investment Position: On February 3, 2026, NAN FUNG TRINITY (HK) LTD disclosed a new position by acquiring 1,492,440 shares of KT Corporation for approximately $28.31 million, marking a strategic expansion in the telecommunications sector.
- Asset Allocation Enhancement: This acquisition positions KT to represent 2.24% of NAN FUNG TRINITY's reportable assets, becoming its 11th largest holding, indicating the firm's confidence in the telecom industry's growth potential.
- Strong Market Performance: As of February 3, 2026, KT shares were priced at $20.90, reflecting a 20.1% increase over the past year, outperforming the S&P 500 by 4.73 percentage points, showcasing market recognition of its business model and growth prospects.
- Valuation at a Discount: NAN FUNG TRINITY purchased KT at a P/E ratio of 15, with a forward P/E ratio of 6, suggesting the investment was made at a reasonable price, with potential for further share accumulation to strengthen its competitive position in the telecom market.
See More
Amcor plc Q2 2026 Earnings Call Highlights
- Stable Financial Performance: Amcor plc reported $5.4 billion in revenue for Q2 2026, with EBITDA at $826 million and adjusted EPS of $0.86, indicating robust financial performance in line with expectations despite weaker noncore business performance, showcasing the company's resilience post-Berry acquisition.
- Accelerated Synergy Realization: The company achieved $55 million in synergy benefits in Q2, a significant increase from $38 million in Q1, with total expected synergies for FY 2026 projected to exceed $260 million, enhancing profitability and laying a foundation for future growth.
- Free Cash Flow Guidance: Management reaffirmed free cash flow guidance for FY 2026 at $1.8 billion to $1.9 billion, reflecting ongoing efforts in cost control and operational efficiency aimed at achieving sustainable earnings growth amidst market challenges.
- Portfolio Optimization Progress: Amcor is evaluating alternatives for its $2.5 billion noncore businesses, including the North American beverage segment, emphasizing the importance of portfolio optimization to enhance overall business performance and maintain a competitive edge in a challenging market environment.
See More
Amcor (AMCR) Q2 2026 Earnings Call Transcript
See More
Amcor Q2 Earnings Beat Expectations with Strong Growth
- Earnings Beat Expectations: Amcor reported Q2 non-GAAP EPS of $0.86, exceeding estimates by $0.02, indicating ongoing improvement in profitability, although revenue of $5.44 billion, up 67.9% year-over-year, fell short of expectations by $70 million.
- Significant Acquisition Synergies: GAAP net income stood at $177 million, including acquisition-related costs, with GAAP diluted EPS at $0.38, while acquisition synergies reached $55 million, demonstrating the strategic success of the Berry acquisition.
- Adjusted EBITDA Growth: Adjusted EBITDA rose to $826 million, an 83% increase, with adjusted EBIT at $603 million, up 66%, reflecting significant improvements in cost control and operational efficiency, as adjusted EBITDA margin reached 15.2%, up from 14% last year.
- Optimistic Future Outlook: Amcor reaffirmed its fiscal 2026 guidance with adjusted EPS expected between $4.00 and $4.15, representing 12% to 17% constant currency growth, alongside projected free cash flow of $1.8 to $1.9 billion, highlighting strong cash generation capabilities.
See More
